Patents by Inventor Tonghui Chen

Tonghui Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAMPTOTHECIN DERIVATIVE FOR TREATING OR PREVENTING CANCER AND ANTIBODY-DRUG CONJUGATE THEREOF
    Publication number: 20260102507
    Abstract: The present invention relates to camptothecin derivatives, their linker-payload conjugates, and antibody-drug conjugates, as well as pharmaceutically acceptable salts or esters, solvates, tautomers, stereoisomers, prodrugs, or isotopically labeled forms thereof, for use in the treatment or prevention of cancer. The invention further relates to a pharmaceutical composition comprising the camptothecin derivatives, their linker-payload conjugates, or antibody-drug conjugates; methods for the preparation of the same; and the use thereof.
    Type: Application
    Filed: December 15, 2025
    Publication date: April 16, 2026
    Inventors: Tonghui CHEN, Jun XU, Tong WANG, Xuerong FANG, Jianyu LIAO, Haoxi HUANG
  • Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof
    Patent number: 12428433
    Abstract: Disclosed are a macrocyclic fluorine-containing heterocyclic derivative of formula (I), a preparation method thereof, and a use thereof in treatment of TRK kinase-mediated diseases.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: September 30, 2025
    Assignee: SCINNOHUB PHARMACEUTICAL CO., LTD
    Inventors: Anle Yang, Haoxi Huang, Tonghui Chen, Jie Liang, Dewei Zhang, Jingen Deng, Hongbo Li, Junjie Pu
  • FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF
    Publication number: 20230044722
    Abstract: Disclosed are a macrocyclic fluorine-containing heterocyclic derivative of formula (I), a preparation method thereof, and a use thereof in treatment of TRK kinase-mediated diseases.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 9, 2023
    Inventors: Anle YANG, Haoxi HUANG, Tonghui CHEN, Jie LIANG, Dewei ZHANG, Jingen DENG, Hongbo LI, Junjie PU
  • Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof
    Patent number: 10793576
    Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: October 6, 2020
    Assignees: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD., CHENGDU HIGHBRED PHARMACEUTICAL CO., LTD.
    Inventors: Yingfu Li, Haoxi Huang, Guanfeng Liu, Tonghui Chen, Junfeng Ren, Zhonghai Su
  • COMPOUND USED AS BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20190315758
    Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.
    Type: Application
    Filed: February 20, 2017
    Publication date: October 17, 2019
    Inventors: Yingfu Li, Haoxi Huang, Guanfeng Liu, Tonghui Chen, Junfeng Ren, Zhonghai Su